Target
GD2
18 abstracts
Abstract
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.Org: Nationwide Children's Hosp, Columbus, OH, OHB Neonatology, Nationwide Childrens Hospital, Nationwide Children's Hospital,
Abstract
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.Org: University of Chicago Medical Center, Chicago, IL, Children's Oncology Group Statistics and Data Center, University of Florida, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Children's Oncology Group Statistics & Data Center, Department of Biostatistics & Data Science,
Abstract
Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine,
Abstract
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.Org: Hospital Sant Joan de Deu,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine, Riley Hospital for Children,
Abstract
Preclinical characterization of pretargeted radioimmunotherapy (PRIT) with GD2-SADA, a self-assembling and disassembling bispecific fusion protein.Org: Y-mAbs Therapeutics, Inc, Y-mAbs A/S, City of Hope National Medical Center, University of Maryland School of Medicine,
Abstract
Efficacy and safety of dinutuximab in the management of high-risk neuroblastoma: A systematic review and meta-analysis.Org: Life Care Hospital and Research Institute,
Abstract
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.Org: Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung GmbH, Schneider Children‘s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Paediatric Haematology Oncology, Jagiellonian University Medical College, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Karolinska Institutet, Childhood Cancer Research Unit,
Abstract
A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, St. Jude Children's Research Hospital, Children's Oncology Group Statistics and Data Center, University of Florida, Children's Hospital Los Angeles Department of Pediatrics,
Abstract
Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.Org: UPMC Hillman Cancer Center, HonorHealth Research Institute, City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University Hospital Siedman Cancer Center,
Abstract
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.Org: Memorial Sloan Kettering Cancer Center,
Abstract
GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of ovarian cancer.Org: AOA Dx Inc, Lady Davis Institute-Jewish General Hospital, McGill University Health Center, University of Montreal Hospital Centre (CRCHUM), University of Montreal,
Abstract
Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label.Org: Bayer HealthCare Pharmaceuticals Inc., Bayer, Xcenda, Xcenda LLC, Bayer Corporation,
Abstract
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Riley Hospital for Children at Indiana University Health, The Warren Alpert Medical School of Brown University, David Geffen School of Medicine UCLA, Cohen Children's Medical Center,
Abstract
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).Org: University Medicine Greifswald, Pediatric Hematology and Oncology, Pediatric Hematology and Oncology, Greifswald, Germany, Pediatric Hematology and Oncology,
Abstract
Reduction in Curie score in neuroblastoma patients treated with naxitamab.Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Hong Kong Children's Hospital, The University of Hong Kong, The Hospital for Sick Children,
Abstract
Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease.Org: Memorial Sloan Kettering Cancer Center,